A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children

Preterm infants ≤ 35 weeks' gestational age (GA), and children ≤ 24 months of age with bronchopulmonary dysplasia (BPD) or hemodynamically significant congenital heart disease (hsCHD) are at high risk for developing severe respiratory syncytial virus (RSV) disease. In 3 previous randomized, pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambrose, Christopher S, Chen, Xin, Kumar, Veena R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443059/
https://www.ncbi.nlm.nih.gov/pubmed/25483483
http://dx.doi.org/10.4161/hv.32082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443059/
https://www.ncbi.nlm.nih.gov/pubmed/25483483
http://dx.doi.org/10.4161/hv.32082

Ejemplares similares